Biochemistry (Moscow)

, Volume 80, Issue 1, pp 74–86 | Cite as

Quantitative analysis of structure-activity relationships of tetrahydro-2H-isoindole cyclooxygenase-2 inhibitors

Article

Abstract

Using the GUSAR program, structure-activity relationships on inhibition of cyclooxygenase-2 (COX-2) catalytic activity were quantitatively analyzed for twenty-six derivatives of 4,5,6,7-tetrahydro-2H-isoindole, 2,3-dihydro-1H-pyrrolyzine, and benzothiophene in the concentration range of 0.6–700 nmol/liter IC50 values. Six statistically significant consensus QSAR models for prediction of IC50 values were designed based on MNA- and QNA-descriptors and their combinations. These models demonstrated high accuracy in the prediction of IC50 values for structures of both training and test sets. Structural fragments of the COX-2 inhibitors capable of strengthening or weakening the desired property were determined using the same program. This information can be taken into consideration on molecular design of new COX-2 inhibitors. It was shown that in most cases, the influence of structural fragments on the inhibitory activity of the studied compounds revealed with the GUSAR program coincided with the results of expert evaluation of their effects based on known experimental data, and this can be used for optimization of structures to change the value of their biological activity.

Key words

cyclooxygenase-2 inhibitors GUSAR QSAR models QNA and MNA descriptors analysis of structure-activity relationships 

Abbreviations

COX-1(2)

cyclooxygenase-1(2)

GUSAR

General Unrestricted Structure-Activity Relationships

MNA

Multilevel Neighborhoods of Atoms

QSAR

Quantitative Structure-Activity Relationships

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zarghi, A., and Arfaei, S. (2011) Selective COX-2 inhibitors: a review of their structure-activity relationships, Iran. J. Pharm. Res., 10, 655–683.PubMedCentralPubMedGoogle Scholar
  2. 2.
    Marnett, L. J. (2009) Mechanisms of cyclooxygenase-2 inhibition and cardiovascular side effects — the plot thickens, Cancer Prev. Res. (Philadelphia), 2, 288–290.CrossRefGoogle Scholar
  3. 3.
    Charlier, C., and Michaux, C. (2003) Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs, Eur. J. Med. Chem., 38, 645–659.PubMedCrossRefGoogle Scholar
  4. 4.
    Smith, W. L., DeWitt, D. L., and Garavito, R. M. (2000) Cyclooxygenases: structural, cellular, and molecular biology, Annu. Rev. Biochem., 69, 145–182.PubMedCrossRefGoogle Scholar
  5. 5.
    Vane, J. R., Bakhle, Y. S., and Botting, R. M. (1998) Cyclooxygenases 1 and 2, Annu. Rev. Pharmacol. Toxicol., 38, 97–120.PubMedCrossRefGoogle Scholar
  6. 6.
    Cha, Y. I., and DuBois, R. N. (2007) NSAIDs and cancer prevention: targets downstream of COX-2, Annu. Rev. Med., 58, 239–252.PubMedCrossRefGoogle Scholar
  7. 7.
    Greenhough, A., Smartt, H. J., Moore, A. E., Roberts, R. R., Williams, A. C., and Kaidi, C. P. A. (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumor microenvironment, Carcinogenesis, 30, 377–386.PubMedCrossRefGoogle Scholar
  8. 8.
    Holtje, H.-D., Sippl, W., Rognan, D., and Folkers, G. (2010) Molecular Modeling: Basic Principles and Applications (Palyulin, V. A., and Radchenko, E. V., eds.) [Russian translation], BINOM, Laboratoriya Znanii, Moscow.Google Scholar
  9. 9.
    Ivanov, A. S., Veselovsky, A. V., Dubanov, A. V., Skvortsov, V. S., and Archakov, A. I. (2006) The integral platform “From gene to drug prototype” in silico and in vitro, Ross. Khim. Zh., L, 18–35.Google Scholar
  10. 10.
    Khan, M. S., and Khan, Z. H. (2003) Molecular modeling for generation of structural and molecular electronic descriptors for QSAR using quantum mechanical semiempirical and ab initio methods, Genome Informatics, 14, 486–487.Google Scholar
  11. 11.
    Filimonov, D. A., and Poroikov, V. V. (2006) Prediction of the biological activity spectrum of organic compounds, Ross. Khim. Zh., L, 66–75.Google Scholar
  12. 12.
    Poroikov, V. V., and Filimonov, D. A. (2001) Computeraided prediction of biological activity of chemical compounds as a basis for search and optimization of basic structures of new drugs, in Nitrous Heterocycles and Alkaloids (Kartsev, V. G., and Tolstikov, G. A., eds.) [in Russian], Iridium-Press, Moscow, Vol. 1, pp. 123–129.Google Scholar
  13. 13.
    Lagunin, A. A., Gloriozova, T. A., Dmitriev, A. V., Volgina, N. E., and Poroikov, V. V. (2012) Computerized assessment of interactions of pharmaceuticals with P-glycoprotein, Byull. Eksp. Biol. Med., 154, 520–524.Google Scholar
  14. 14.
    Zakharov, A. V., Lagunin, A. A., Filimonov, D. A., and Poroikov, V. V. (2012) Quantitative prediction of antitarget interaction profiles for chemical compounds, Chem. Res. Toxicol., 25, 2378–2385.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Lagunin, A., Zakharov, A., Filimonov, D., and Poroikov, V. (2011) QSAR modeling of rat acute toxicity on the basis of PASS prediction, Mol. Informatics, 30, 241–250.CrossRefGoogle Scholar
  16. 16.
    Filimonov, D. A., Zakharov, A. V., Lagunin, A. A., and Poroikov, V. V. (2009) QNA based “Star Track” QSAR approach, SAR QSAR Environ. Res., 20, 679–709.PubMedCrossRefGoogle Scholar
  17. 17.
    Masanda, V. H., Mahajana, D. T., Patil, K. N., Dawale, N. E., Hadda, T. B., Alafeefy, A. A., and Chinchkhede, K. D. (2011) General unrestricted structure activity relationships based evaluation of quinoxaline derivatives as potential influenza NS1A protein inhibitors, Der Pharma Chemica, 3, 517–525.Google Scholar
  18. 18.
    Kokurkina, G. V., Dutov, M. D., Shevelev, S. A., Popkov, S. V., Zakharov, A. V., and Poroikov, V. V. (2011) Synthesis, antifungal activity and QSAR study of 2-arylhydroxynitroindoles, Eur. J. Med. Chem., 46, 4374–4382.PubMedCrossRefGoogle Scholar
  19. 19.
    Taipov, I. A., Khayrullina, V. R., Gerchikov, A. Ya., Khoma, V. K., Zarudiy, and Begel, Kh. (2012) Virtual screening in the row of effective inhibitors of catalytic activity of leukotriene-A4-hydrolase, Vestnik Bashkir. Univ., 17, 886–891.Google Scholar
  20. 20.
    Tarasov, G. P., Khairullina, V. R., Gerchikov, A. Ya., Kirlan, S. A., and Zarudiy, F. S. (2012) Derivatives of 4-amino-N-[2-(diethylamino)ethyl]benzamide as potentially low toxicity substances with a pronounced anti-arrhythmic action, Vestnik Bashkir. Univ., 17, 1242–1246.Google Scholar
  21. 21.
    Khayrullina, V. R., Kirlan, S. A., Gerchikov, A. Ya., Zarudiy, F. S., Dimoglo, A. S., and Kantor, E. A. (2010) Modeling structures of anti-inflammatory compounds on considering their toxicity, Bashkir. Khim. Zh., 17, 76–79.Google Scholar
  22. 22.
  23. 23.
  24. 24.
    Portevin, B., Tordjman, C., Pastoureau, P., Bonnet, J., and De Nanteuil, G. (2000) 1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives: a new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite, J. Med. Chem., 43, 4582–4593.PubMedCrossRefGoogle Scholar
  25. 25.
    Lagunin, A., Filimonov, D., Zakharov, A., Xie, W., Huang, Y., Zhu, F., Shen, T., Yao, J., and Poroikov, V. (2009) Computeraided prediction of rodent carcinogenicity by PASS and CISOC-PSCT, QSAR Combinator. Sci., 28, 806–810.CrossRefGoogle Scholar
  26. 26.
    Silakari, P., Shrivastava, S. D., Silakari, G., Kohli, D. V., Rambabu, G., Srivastava, S., Shrivastava, S. K., and Silakari, O. (2008) QSAR analysis of 1,3-diaryl-4,5,6,7-tetrahydro-2H derivatives as selective COX-2 inhibitors, Eur. J. Med. Chem., 43, 1559–1569.PubMedCrossRefGoogle Scholar
  27. 27.
    Ravdel, A. A., and Ponomareva, A. M. (eds.) (2003) Short Reference Book of Physicochemical Values [in Russian], Ivan Fedorov, St. Petersburg, pp. 212–213.Google Scholar

Copyright information

© Pleiades Publishing, Ltd. 2015

Authors and Affiliations

  1. 1.Faculty of ChemistryBashkir State UniversityUfaRussia
  2. 2.Medico-Biological FacultyPirogov Russian National Research Medical UniversityMoscowRussia
  3. 3.Orekhovich Institute of Biomedical ChemistryRussian Academy of Medical SciencesMoscowRussia
  4. 4.Bashkir State Medical UniversityUfaRussia

Personalised recommendations